three new approaches to cancer treatment are giving promising results in early clinical tests an oncology conference in london was told yesterday all three result from collaborative research involving scotia pharmaceuticals a ukcanadian drug company and university medical centres in the uk and overseas potentially the most farreaching treatment is a tumourkilling drug ef13 which scotia described as a magic bullet which could destroy cancer cells without harming normal tissues preliminary clinical trials indicate that the drug may double the survival time of patients with latestage pancreatic and breast cancers the doctors involved however are wary of making extravagant claims for what is still an experimental drug ef13 seems to have important therapeutic effects without harming the patients said mr ken fearon from edinburgh universitys department of surgery it really is different from anything else available dr david horrobin scotia chief executive said ef13 was developed not to be a more potent cell killer than other cancer drugs but to be free of the toxic side effects which make conventional chemotherapy so unpleasant it is similar chemically to evening primrose oil which has until recently been the main source of income for his company the second new drug ef27 reduces the harmful effects of radiotherapy trials by the radiobiology research group at oxfords churchill hospital show that the drug can protect normal tissue from radiation damage while enhancing the damage caused to cancer cells the third drug ef9 is a lightactivated chemical designed to improve a form of cancer treatment known as photodynamic therapy ef9 destroys cancer cells when the tumour is illuminated by laser if the treatments continue to show promise they could be available commercially within three or four years